Targeted Oncology36m
FDA OKs TLX007-CDx in Prostate Cancer Treatment
TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...
The Manila Times37m
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one ...
Opinion
Crikey48mOpinion
Of course Australia’s PBS is despised — it values safety, low prices and best value
Big pharma coming after the PBS is a compliment — it shows that the scheme works in the best interests of people, not the markets.
BioSpace53m
Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...